Korea Needs ‘More Unified’ Bio-Health Care Policy: Experts
This article was originally published in PharmAsia News
At a recent seminar in Seoul, South Korean biotechnology and health care experts positively assessed the government's ongoing efforts to nurture the sector, but called for more unified policies and clearer objectives going forward.
You may also be interested in...
Amid the recent ousting of President Park Geun-hye amid corruption allegations and a new presidential election only weeks away, the South Korean pharma industry is quickening its calls for policy support from the next administration by recommending a variety of changes.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Hanmi Pharm is remaining upbeat after Sanofi’s decision to find another commercialization partner for efpeglenatide, saying it was the best strategy for the long-acting GLP-1 agonist given the strategic change in the big pharma’s diabetes strategy.